TipRanks on MSN
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MG is a Phase 1/2 clinical study conducted by Cabaletta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback